Galectin Therapeutics's total assets for Q4 2025 were $19.53M, an increase of 51.82% from the previous quarter. GALT total liabilities were $145.73M for the fiscal quarter, a 5.47% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.